Chemed reported second-quarter earnings that fell short of analysts' expectations, causing its share price to tumble. While Chemed grew sales by 4% in Q2, adjusted earnings per share (EPS) declined by a staggering 22%. Meanwhile, management cut 2025 EPS guidance from $25.20 to$22.15, implying a 4% decline from last year's earnings. Adding further uncertainty, the company announced Nick Westfall, CEO of Vitas Healthcare, was stepping down. Chemed missed expectations on both the top and bottom lines with its ...